Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed in the medical termination of intra‑uterine pregnancy up to 10 weeks gestation in women seeking a non‑surgical option.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics and comprehensive documentation and timely.

Mifegyne is a progesterone receptor antagonist used in early pregnancy management. - Intrauterine pregnancy ≤10 weeks: enables medical termination of early pregnancy. - Combination therapy with misoprostol: provides the first step in a two‑drug regimen for termination. - Pre‑surgical preparation: used to soften the decidua before surgical evacuation when medically indicated.

Mifegyne may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vaginal bleeding: irregular or prolonged spotting. - Cramping: uterine pain resembling menstrual cramps. - Fatigue: transient tiredness. - Diarrhea: loose stools in some patients. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Heavy hemorrhage: excessive bleeding requiring medical attention. - Infection: signs of uterine or systemic infection. - Allergic reaction: rash, swelling, or anaphylaxis. - Incomplete abortion: retained tissue necessitating further intervention.

Before prescribing Mifegyne, clinicians should consider several safety measures. - Confirm gestational age: ensure pregnancy is ≤10 weeks by ultrasound. - Assess contraindications: exclude ectopic pregnancy, chronic adrenal failure, or anticoagulant therapy. - Provide counseling: discuss expected bleeding patterns and signs of complications. - Arrange follow‑up: schedule post‑treatment evaluation to confirm complete evacuation. - Review medication history: avoid concomitant use of CYP3A4 inducers that may reduce efficacy. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Mifegyne can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Rifampicin: strong CYP3A4 inducer that may markedly lower mifepristone levels. - Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase plasma concentration. - Hormonal contraceptives: potential reduced efficacy, advise alternative contraception. - NSAIDs: may exacerbate gastrointestinal irritation.